Pharmaceuticals giant Pfizer (NYSE:PFE) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts’ consensus estimates. The company reported an adjusted earnings per share of $0.63, significantly above the analyst consensus of $0.47, while generating revenue of $17.76 billion, surpassing expectations of $17.35 billion.
Despite a significant year-over-year decline in Comirnaty revenue, the overall performance was strong, driven by growth in non-COVID-19 products and strategic acquisitions.
MetricQ4 2024Q4 EstimateQ4 2023Change (YOY)Adjusted EPS$0.63$0.47$0.10N/MRevenue$17.76 billion$17.35 billion$14.57 billion22%Adjusted net income$3.59 billionN/A$0.59 billionN/MComirnaty revenue$3.38 billionN/A$5.36 billion(37%)
Source: Pfizer. Note: Analyst consensus estimates for the quarter provided by FactSet. N/M = Change figures are not meaningful due to a one-time, non-cash revenue reversal of $3.5 billion related to its COVID-19 antiviral Paxlovid in the fourth quarter of 2023.
Pfizer, a renowned biopharmaceutical company, excels in discovering and developing innovative medicines and vaccines. Its broad portfolio spans oncology, vaccines, and other therapeutic areas. The company commands a significant market position due to its extensive product pipeline and strategic acquisitions.
Recently, Pfizer has concentrated on expanding its oncology segment, enhanced by the March 2023 acquisition of Seagen. This focus on oncology highlights the importance of research and development (R&D) in driving sustainable growth. R&D is crucial in launching new therapies and maintaining Pfizer’s competitive edge.
Total revenue of $17.8 billion in the quarter was up 22% year over year thanks, in part, to its oncology portfolio delivering 27% growth, driven by products like Padcev and Adcetris following the Seagen acquisition.
The Vyndaqel family of drugs recorded a remarkable 61% growth, aided by increased patient diagnoses and heightened demand. Meanwhile, Comirnaty revenue plummeted by 37%, reflecting COVID-19’s evolution into a seasonal ailment. This trend underscores the need for product diversification.
Cost reduction efforts culminated in a significant $3.59 billion adjusted net income. Paxlovid sales came in at $727 million compared to a $3.14 billion loss in 2023’s Q4 driven by a $3.5 billion revenue reversal brought on by the company’s transition to traditional commercial market sales in the U.S. and away from government-related sales for the antiviral treatment.
Strategic acquisitions, like the integration of Seagen’s assets, were vital in enhancing the earnings performance. Despite a drop in legacy product sales like Xeljanz, Pfizer demonstrated resilience through effective cost management.
Notably, Pfizer’s R&D expenditure rose by 8% operationally, reinforcing its pipeline’s strength. These investments were essential for continued product development and sustained leadership in the pharmaceutical industry. Through strategic acquisitions, Pfizer bolstered its oncology offerings, crucial for future growth.
Throughout the quarter, Pfizer enhanced shareholder value with a strong capital allocation strategy, which included the sale of $3.5 billion worth of Haleon shares, strengthening its financial position.
Pfizer reaffirmed its 2025 financial guidance, anticipating revenues between $61 billion to $64 billion and adjusted EPS ranging from $2.80 to $3. The company intends to intensify its cost-efficiency measures to navigate patent expirations and regulatory headwinds.
Investors should monitor Pfizer’s strategic focus on R&D and pipeline advancements, particularly in oncology and vaccines. The company’s ability to diversify product lines while managing existing product lifecycles is critical for long-term growth. Moreover, attention should be paid to mitigating challenges presented by legislative shifts such as the Inflation Reduction Act.
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 895% — a market-crushing outperformance compared to 176% for the S&P 500.*
They just revealed what they believe are the 10 best stocks for investors to buy right now…
*Stock Advisor returns as of February 3, 2025
JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
